Market Overview:
The global glomerulonephritis treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of glomerulonephritis, rising awareness about available treatments, and technological advancements in the field of nephrology. The global glomerulonephritis treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ACH-5228, AMY-101, Atacicepts AVX-002), and others. On the basis of application,the market is segmented into home care,, clinic,, and hospital). The regional segments are North America,, Latin America,, Europe Asia Pacific ,and Middle East & Africa ).
Product Definition:
Glomerulonephritis Treatment is the administration of drugs or therapies to treat glomerulonephritis. Glomerulonephritis Treatment is important because it can help prevent kidney damage and improve the patient's prognosis.
ACH-5228:
ACH-5228 is a novel oral drug developed by the pharmaceutical company Merck KGaA. It's an angiotensin II receptor blocker and was first approved in Japan in 2016, then in Europe and the U.S. in 2017 and 2018 respectively.
AMY-101:
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects the nerve cells in the brain and the spinal cord responsible for controlling muscle movement. As per the National Institute of Neurological Disorders and Stroke (NINDS) fact sheet, around 10-15% of people suffering from ALS are prone to develop kidney failure.
Application Insights:
Glomerulonephritis treatment in hospital accounted for the largest revenue share in 2017. Hospital-based settings offer convenience and ease of access for patients who require immediate medical attention. Moreover, hospitals provide a safe environment where nephrological procedures can be performed efficiently owing to the availability of advanced healthcare facilities and equipment. The rising prevalence of glomerulonephritis coupled with increasing awareness is anticipated to boost segment growth over the forecast period.
The home care application segment is expected to register significant growth during the forecast period due to increasing cases of geriatric population suffering from various chronic diseases including heart diseases, hypertension, diabetes mellitus type 2 as well as kidney disease requiring long term care services at their homes or some other place convenient for them near their homes. This has ledto an increase in demand for glomerulonephritis treatment medicines which are used commonly by most doctors when treating these conditions at home thus driving market growth during this period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for novel therapies are some factors responsible for its large share. Moreover, increasing cases of kidney diseases due to a rise in the aging population is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments and private organizations as well as growing awareness about available treatment options among patients.
Growth Factors:
- Increasing incidence of glomerulonephritis
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective treatments for glomerulonephritis
- Technological advancements in the field of nephrology and renal care
- Growing number of research studies on glomerulonephritis
Scope Of The Report
Report Attributes
Report Details
Report Title
Glomerulonephritis Treatment Market Research Report
By Type
ACH-5228, AMY-101, Atacicept, Avacopan, AVX-002
By Application
Home Care, Clinic, Hospital
By Companies
Achillion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, Bristol-Myers Squibb Company, Cellmid Ltd, ChemoCentryx Inc, Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Merck KGaA, Omeros Corp, Pfizer Inc, Pharmalink AB, Ra Pharmaceuticals Inc, Retrophin Inc, Rigel Pharmaceuticals Inc, Takeda, Visterra Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Glomerulonephritis Treatment Market Report Segments:
The global Glomerulonephritis Treatment market is segmented on the basis of:
Types
ACH-5228, AMY-101, Atacicept, Avacopan, AVX-002
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Home Care, Clinic, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Achillion Pharmaceuticals Inc
- Anthera Pharmaceuticals Inc
- Biogen Inc
- Bristol-Myers Squibb Company
- Cellmid Ltd
- ChemoCentryx Inc
- Complexa Inc
- Dimerix Bioscience Pty Ltd
- GlaxoSmithKline Plc
- Merck KGaA
- Omeros Corp
- Pfizer Inc
- Pharmalink AB
- Ra Pharmaceuticals Inc
- Retrophin Inc
- Rigel Pharmaceuticals Inc
- Takeda
- Visterra Inc
Highlights of The Glomerulonephritis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACH-5228
- AMY-101
- Atacicept
- Avacopan
- AVX-002
- By Application:
- Home Care
- Clinic
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glomerulonephritis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glomerulonephritis is a kidney disease that causes inflammation and damage to the glomeruli, which are small filtering units in the kidneys. Treatment typically includes medications to reduce inflammation and pain relief, as well as dialysis or a kidney transplant if available.
Some of the major companies in the glomerulonephritis treatment market are Achillion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, Bristol-Myers Squibb Company, Cellmid Ltd, ChemoCentryx Inc, Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Merck KGaA, Omeros Corp, Pfizer Inc, Pharmalink AB, Ra Pharmaceuticals Inc, Retrophin Inc, Rigel Pharmaceuticals Inc, Takeda, Visterra Inc.
The glomerulonephritis treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glomerulonephritis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glomerulonephritis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glomerulonephritis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glomerulonephritis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glomerulonephritis Treatment Market Size & Forecast, 2020-2028
4.5.1 Glomerulonephritis Treatment Market Size and Y-o-Y Growth
4.5.2 Glomerulonephritis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ACH-5228
5.2.2 AMY-101
5.2.3 Atacicept
5.2.4 Avacopan
5.2.5 AVX-002
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Home Care
6.2.2 Clinic
6.2.3 Hospital
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glomerulonephritis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glomerulonephritis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ACH-5228
9.6.2 AMY-101
9.6.3 Atacicept
9.6.4 Avacopan
9.6.5 AVX-002
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Home Care
9.10.2 Clinic
9.10.3 Hospital
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ACH-5228
10.6.2 AMY-101
10.6.3 Atacicept
10.6.4 Avacopan
10.6.5 AVX-002
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Home Care
10.10.2 Clinic
10.10.3 Hospital
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ACH-5228
11.6.2 AMY-101
11.6.3 Atacicept
11.6.4 Avacopan
11.6.5 AVX-002
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Home Care
11.10.2 Clinic
11.10.3 Hospital
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ACH-5228
12.6.2 AMY-101
12.6.3 Atacicept
12.6.4 Avacopan
12.6.5 AVX-002
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Home Care
12.10.2 Clinic
12.10.3 Hospital
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ACH-5228
13.6.2 AMY-101
13.6.3 Atacicept
13.6.4 Avacopan
13.6.5 AVX-002
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Home Care
13.10.2 Clinic
13.10.3 Hospital
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glomerulonephritis Treatment Market: Competitive Dashboard
14.2 Global Glomerulonephritis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Achillion Pharmaceuticals Inc
14.3.2 Anthera Pharmaceuticals Inc
14.3.3 Biogen Inc
14.3.4 Bristol-Myers Squibb Company
14.3.5 Cellmid Ltd
14.3.6 ChemoCentryx Inc
14.3.7 Complexa Inc
14.3.8 Dimerix Bioscience Pty Ltd
14.3.9 GlaxoSmithKline Plc
14.3.10 Merck KGaA
14.3.11 Omeros Corp
14.3.12 Pfizer Inc
14.3.13 Pharmalink AB
14.3.14 Ra Pharmaceuticals Inc
14.3.15 Retrophin Inc
14.3.16 Rigel Pharmaceuticals Inc
14.3.17 Takeda
14.3.18 Visterra Inc
